凯莱通(新)KLTTBAv3.pptxVIP

凯莱通;镇痛;凯莱通为中枢性α2受体激动剂，通过增强运动神经元的突触前抑制作用而降低强直性痉挛状态。即，降低高肌张力。 对骨骼肌纤维和神经肌肉接头没有直接作用。所以，凯莱通降低肌张力而不影响肌力。;凯莱通 药代动力学;凯莱通的抗痉挛作用;痉挛，是上运动神经元（Upper Motor Neuron，UMN）受损的表现，其特征是肌张力增强。尽管不了解痉挛的确切发病率，但它可能影响约1.2亿的世界人口。 卒中偏瘫后的肌张力增高一般在发病后3周出现，发生率约65%，是造成运动功能难以恢复的主要原因。;Muscles immobilized at short length develop altered length–tension relationships that make them shorter and stiffer;口服抗痉挛药是康复治疗的一线选择 Oral antispastic agents are first-line treatment for the pharmacological management of generalized spasticity following physical therapy. 最好的方法是口服抗痉挛药与康复训练结合 They are best used along with physical measures to reduce tone in the limbs and trunk and can be employed in combination with other therapeutic agents. 口服抗痉挛药具有不可替代的重要地位 Spasticity management is a team responsibility designed to address the needs of the disabled individuals and the carer. The place of oral antispastic agents has been well established.;Mariko Kita and Donald E. Goodkin. Drugs Used to Treat Spasticity. Drugs 2000 Mar; 59 (3): 487-495；Leonard Kamen, et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current Medical Research and Opinion 2008,24(2): 425~439；Christopher J.Mathias, et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. Journal of Rehabilitation Research and Development. 1989,26(4): 9-16;凯莱通 1hr起效，作用持续达6hr;凯莱通 口服1hr后的电生理学改变;Leonard Kamen, et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current Medical Research and Opinion 2008,24(2): 425~439;Leonard Kamen, et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Current Medical Research and Opinion 2008,24(2): 425~439;崔利华（北京博爱医院）。三种抗痉挛药物治疗卒中后肢体痉挛的疗效比较。中国脑血管病杂志2009,6(9): 466~470;崔利华。三种抗痉挛药物治疗卒中后肢体痉挛的疗效比较。中国脑血管病杂志2009,6(9): 466~470;Muscle strength (modified BMRC scale);凯莱通